Urology
Volume 72, Issue 6 , Pages 1212-1213 , December 2008

Reply

  • Umberto Capitanio, M.D.

      Affiliations

    • Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada; and Department of Urology, Vita-Salute San Raffaele, Milan, Italy
    • ,
  • Sasha Ahyai, M.D.

      Affiliations

    • Department of Urology, University of Hamburg, Hamburg, Germany
    • ,
  • Markus Graefen, M.D.

      Affiliations

    • Department of Urology, University of Hamburg, Hamburg, Germany
    • ,
  • Andreas Erbersdobler, M.D.

      Affiliations

    • Department of Urology, University of Hamburg, Hamburg, Germany
    • ,
  • Thorsten Schlomm, M.D.

      Affiliations

    • Department of Urology, University of Hamburg, Hamburg, Germany
    • ,
  • Alexander Haese, M.D.

      Affiliations

    • Department of Urology, University of Hamburg, Hamburg, Germany
    • ,
  • Thomas Steuber, M.D.

      Affiliations

    • Department of Urology, University of Hamburg, Hamburg, Germany
    • ,
  • Hans Heinzer, M.D.

      Affiliations

    • Department of Urology, University of Hamburg, Hamburg, Germany
    • ,
  • Hartwig Huland, M.D.

      Affiliations

    • Department of Urology, University of Hamburg, Hamburg, Germany
    • ,
  • Claudio Jeldres, M.D.

      Affiliations

    • Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada; and Department of Urology, University of Montreal, Montreal, Quebec, Canada
    • ,
  • Pierre I. Karakiewicz, M.D.

      Affiliations

    • Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada; and Department of Urology, University of Montreal, Montreal, Quebec, Canada
    • ,
  • Shahrokh F. Shariat, M.D.

      Affiliations

    • Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada
    • ,
  • Paul Perrotte, M.D.

      Affiliations

    • Department of Urology, University of Montreal, Montreal, Quebec, Canada
    • ,
  • François Péloquin, M.D.

      Affiliations

    • Department of Urology, University of Montreal, Montreal, Quebec, Canada
    • ,
  • Daniel Pharand, M.D.

      Affiliations

    • Department of Urology, University of Montreal, Montreal, Quebec, Canada
    • ,
  • Philippe Arjane, M.D.

      Affiliations

    • Department of Urology, University of Montreal, Montreal, Quebec, Canada

References 

  1. Kattan MW, Eastham JA, Wheeler TM, et al. Counseling men with prostate cancer: A nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol. 2003;170:1792–1797
  2. Steyerberg EW, Roobol MJ, Kattan MW, et al. Prediction of indolent prostate cancer: Validation and updating of a prognostic nomogram. J Urol. 2007;177:107–112
  3. Dong F, Kattan MW, Steyerberg EW, et al. Validation of pretreatment nomograms for predicting indolent prostate cancer: Efficacy in contemporary urological practice. J Urol. 2008;180:150–154
  4. Jeldres C, Suardi N, Walz J, et al. Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men. Epub Eur Urol. 2007;Dec 7
  5. Chun FK, Haese A, Ahyai SA, et al. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Epub Cancer. 2008;June 13
  6. Bastian PJ, Mangold LA, Epstein JI, et al. Characteristics of insignificant clinical T1c prostate tumors: A contemporary analysis. Cancer. 2004;101:2001–2005
  7. Suardi N, Capitanio U, Chun F KH, et al. Currently used criteria for active surveillance in men with low risk prostate cancer (An analysis of pathological features). Cancer. 2008;113:2068–2072

PII: S0090-4295(08)00781-4

doi: 10.1016/j.urology.2008.06.030

Urology
Volume 72, Issue 6 , Pages 1212-1213 , December 2008

Article Tools